8-K: STERIS Reports Strong Fiscal 2026 Results, Approves $1B Buyback

STERIS plc announced robust financial results for fiscal year 2026, with revenue up 9% and adjusted EPS increasing to $10.17, alongside a new $1 billion share repurchase program.

Summary

• STERIS plc reported strong financial results for the fiscal year ended March 31, 2026.
• Full-year revenue from continuing operations increased by 9% to $5.9 billion, with constant currency organic revenue growth of 7%.
• Reported diluted EPS from continuing operations rose to $7.93, and adjusted EPS per diluted share increased to $10.17.
• The company's Board of Directors approved a new $1 billion share repurchase program.
• Fourth-quarter revenue grew 7% to $1.6 billion, with constant currency organic revenue growth of 5%.
• Net income from continuing operations for the full year was $782.3 million.
• Free cash flow for fiscal year 2026 was $982.9 million, an increase from $787.2 million in the prior year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with record revenue, significant EPS growth, and a substantial new share repurchase program indicating management's confidence in future performance.

Positives

• Full-year revenue from continuing operations increased 9% to $5.9 billion.
• Constant currency organic revenue growth for the full year was 7%.
• Reported diluted EPS from continuing operations increased to $7.93 for the full year.
• Adjusted EPS per diluted share increased to $10.17 for the full year.
• Fourth-quarter revenue increased 7% to $1.6 billion.
• Net income from continuing operations for the full year was $782.3 million.
• Free cash flow for fiscal year 2026 was $982.9 million, up from $787.2 million in fiscal 2025.
• A new $1 billion share repurchase program has been authorized by the Board of Directors.

Negatives

• The increase in Healthcare segment operating income was significantly offset by tariffs and inflation.
• Applied Sterilization Technologies (AST) segment experienced a 62% decline in capital equipment revenue.
• Operating income in the Healthcare segment was partially offset by tariffs and inflation.
• Capital expenditures are anticipated to be approximately $375 million for fiscal 2027, including a strategic investment in a new sterility assurance manufacturing plant.

Risks

• Potential for international unrest, military conflicts, economic downturns, currency fluctuations, and cybersecurity events.
• Changes in healthcare policy or government/third-party payor reimbursement levels.
• Compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of pending litigation.
• Changes in tax laws or interpretations, or adoption of income tax treaties, that could increase consolidated tax liabilities.
• Impact of tariffs and/or other trade barriers as a result of STERIS's corporate structure.
• Increasing consolidation and competition within the industry may exert pressure on pricing and manufacturing strategies.
• Labor-related issues such as strikes, unsuccessful union negotiations, and workforce disruptions.
• Inability to recruit or retain management and other personnel.

Future Outlook

For fiscal year 2027, STERIS expects reported revenue to increase by 7-8%, with constant currency organic revenue growth anticipated at 6-7%. Adjusted earnings per diluted share are projected to be between $11.10 and $11.30, representing a 9-11% increase. Capital expenditures are estimated at $375 million, and free cash flow is expected to be approximately $850 million. This outlook includes a strategic investment of $60 million over two years for a new sterility assurance manufacturing plant in Mentor, Ohio, expected to be operational by late calendar 2027.

Management Comments

• "Fiscal 2026 was another record year," said Dan Carestio, President and CEO of STERIS.
• "Our diversified Customer base and growth in procedure volumes continue to drive our performance."
• "We appreciate the efforts of our global Associates who continue to put our Customers first."
• "As we look ahead, we are excited for what is to come as we capitalize on our unique ability to help our Customers enable procedural growth, deliver quality outcomes and drive compliance with standardization and optimization."

Industry Context

StockSavvy.ai notes that STERIS's performance in fiscal year 2026, with consistent revenue growth and strong adjusted EPS, aligns with a trend of resilience in the healthcare and life sciences sectors. The company's focus on infection prevention and enabling procedural growth positions it well within an industry prioritizing safety and efficiency.

Comparison to Industry Standards

• STERIS's reported full-year revenue growth of 9% and constant currency organic revenue growth of 7% generally outperform the average growth rates seen in the broader medical device and healthcare services industries, which have faced supply chain and inflationary pressures.
• The adjusted EPS growth of 9-11% projected for fiscal 2027 indicates strong profitability management, often exceeding industry benchmarks that are impacted by rising operational costs.
• The company's free cash flow generation of $982.9 million in FY26 demonstrates robust operational efficiency, a key metric that many competitors in the medical technology space strive to achieve amidst capital-intensive operations.

Legal Proceedings

• The filing mentions the Illinois EO litigation settlement as an adjustment in the consolidated statements of operations.

Stakeholder Impact

• Shareholders: Benefit from the new $1 billion share repurchase program, potentially increasing shareholder value through reduced share count and increased EPS.
• Employees: Continued growth and investment in facilities like the new manufacturing plant suggest job security and potential for expansion.
• Customers: The company's focus on enabling procedural growth, delivering quality outcomes, and driving compliance is expected to continue benefiting customers.
• Suppliers: Increased demand from revenue growth and investment in new facilities may lead to sustained or increased business opportunities.

Next Steps

• Management will host a conference call on May 12, 2026, to discuss the financial results.
• A new $1 billion share repurchase program will be executed.
• Construction and development of a new sterility assurance manufacturing plant in Mentor, Ohio, is planned, with an anticipated operational date by late calendar 2027.

Key Dates

Recommendation

The company delivered record results, exceeding prior year performance across key metrics like revenue and EPS. The strong free cash flow generation, coupled with a significant new share repurchase authorization and a positive outlook for fiscal 2027, indicates robust financial health and management confidence. These factors collectively suggest a strong investment case.

Keywords

STERIS plc, 8-K, Financial Results, Fiscal Year 2026, Revenue Growth, EPS, Share Repurchase, Healthcare